<DOC>
	<DOC>NCT03062176</DOC>
	<brief_summary>The Interleukin-1 Blockade for the Treatment of Heart Failure in Patients with End-stage Renal Disease (End-stage renal disease and Heart fAilure - Anakinra Remodeling Trial) is a Phase 2, single-arm trial designed to estimate the effect of anakinra, a recombinant human Interleukin-1 (IL-1) receptor antagonist, on cardiorespiratory fitness in patients with end-stage renal disease and heart failure.</brief_summary>
	<brief_title>Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With End-stage Renal Disease (E-HART)</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Heart Failure, Systolic</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Written informed consent 18 years or older Chronic heart failure Left ventricular ejection fraction less than 50% Creactive protein greater than or equal to 2 mg/L Maintenance hemodialysis Inability to complete maximal cardiopulmonary exercise testing Need for urgent or emergent care Recent use of immunosuppressant, antiinflammatory therapies or active rheumatologic disease Allergy to rubber, latex, Escherichia coli or anakinra</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>End-stage renal disease</keyword>
	<keyword>Interleukin-1</keyword>
	<keyword>Interleukin-1 receptor antagonist</keyword>
	<keyword>Metabolomics</keyword>
	<keyword>Lipidomics</keyword>
</DOC>